Inovio Doses 1st Subject in Phase 1/2 Clinical Trial for Vaccine Against Deadly MERS Infection

PLYMOUTH MEETING, Pa., Sept. 5 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today announced the dosing of the first subject with its vaccine to prevent infection from the deadly MERS virus (Middle East Respiratory Syndrome) in a Phase 1/2a study to evaluate INO-4700 (or GLS-5300). The trial is ongoing in South Korea sponsored [...]